| MCD |
Report |
Adjusted diluted EPS |
IN-LINE |
pred $3.33 vs. cons $3.323 (Visible Alpha, Aug. 3 2026) |
MEDIUM |
| MCD |
Report |
Global comparable sales |
BEAT |
pred +1.30% vs. cons +1.19% (Visible Alpha, Aug. 3 2026) |
MEDIUM |
| MCD |
Report |
U.S. comparable sales |
BEAT |
pred +0.90% vs. cons +0.76% (Visible Alpha, Aug. 3 2026) |
MEDIUM |
| MCD |
Guide |
FY26 operating margin |
UNCHANGED |
guide mid- to high-40% vs. cons 47.2% |
MEDIUM |
| MCD |
Guide |
3Q26 global-comp commentary |
LOWER |
guide ~+1.8% vs. cons +2.17% |
LOW |
| MCD |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
LOW |
| MCD |
Return |
5-day cumulative residual |
-2.5% (FADE) |
FADE — maintained FY framework leaves implicit out-period risk |
LOW |